# Modified CV Regimen in Optic Pathway Glioma

> **NCT05278715** · PHASE2 · RECRUITING · sponsor: **Beijing Sanbo Brain Hospital** · enrollment: 75 (estimated)

## Conditions studied

- Optic Glioma
- Pediatric Brain Tumor, Optic Nerve Glioma

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Vincristine
- **DRUG:** Recombinant human endostatin

## Key facts

- **NCT ID:** NCT05278715
- **Lead sponsor:** Beijing Sanbo Brain Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-13
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05278715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05278715, "Modified CV Regimen in Optic Pathway Glioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05278715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*